BNP Paribas Financial Markets’s Rocket Pharmaceuticals RCKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.32M | Buy |
387,065
+117,859
| +44% | +$392K | ﹤0.01% | 3119 |
|
|
2026
Q1 | $964K | Buy |
269,206
+154,041
| +134% | +$612K | ﹤0.01% | 3157 |
|
|
2025
Q4 | $404K | Sell |
115,165
-262,419
| -69% | -$898K | ﹤0.01% | 3685 |
|
|
2025
Q3 | $1.23M | Sell |
377,584
-77,056
| -17% | -$243K | ﹤0.01% | 2985 |
|
|
2025
Q2 | $1.11M | Buy |
454,640
+320,746
| +240% | +$1.62M | ﹤0.01% | 2844 |
|
|
2025
Q1 | $893K | Sell |
133,894
-24,545
| -15% | -$242K | ﹤0.01% | 2868 |
|
|
2024
Q4 | $1.99M | Buy |
158,439
+119,482
| +307% | +$1.8M | ﹤0.01% | 2366 |
|
|
2024
Q3 | $720K | Buy |
38,957
+27,914
| +253% | +$572K | ﹤0.01% | 2690 |
|
|
2024
Q2 | $238K | Sell |
11,043
-31,495
| -74% | -$723K | ﹤0.01% | 3041 |
|
|
2024
Q1 | $1.15M | Sell |
42,538
-44,049
| -51% | -$1.25M | ﹤0.01% | 2405 |
|
|
2023
Q4 | $2.6M | Buy |
86,587
+25,081
| +41% | +$554K | ﹤0.01% | 1798 |
|
|
2023
Q3 | $1.26M | Buy |
61,506
+11,072
| +22% | +$201K | ﹤0.01% | 2178 |
|
|
2023
Q2 | $1M | Sell |
50,434
-68,689
| -58% | -$1.39M | ﹤0.01% | 2196 |
|
|
2023
Q1 | $2.04M | Buy |
119,123
+61,779
| +108% | +$1.21M | ﹤0.01% | 1793 |
|
|
2022
Q4 | $1.12M | Sell |
57,344
-127,445
| -69% | -$2.35M | ﹤0.01% | 2094 |
|
|
2022
Q3 | $2.95M | Buy |
184,789
+167,412
| +963% | +$2.61M | ﹤0.01% | 1677 |
|
|
2022
Q2 | $239K | Sell |
17,377
-44,808
| -72% | -$534K | ﹤0.01% | 3008 |
|
|
2022
Q1 | $986K | Buy |
62,185
+15,392
| +33% | +$266K | ﹤0.01% | 2330 |
|
|
2021
Q4 | $1.02M | Buy |
46,793
+37,220
| +389% | +$1.02M | ﹤0.01% | 2575 |
|
|
2021
Q3 | $286K | Sell |
9,573
-111,471
| -92% | -$4.06M | ﹤0.01% | 2924 |
|
|
2021
Q2 | $5.36M | Buy |
121,044
+111,911
| +1,225% | +$4.86M | 0.01% | 1248 |
|
|
2021
Q1 | $405K | Buy |
9,133
+3,817
| +72% | +$210K | ﹤0.01% | 2683 |
|
|
2020
Q4 | $292K | Sell |
5,316
-3,225
| -38% | -$118K | ﹤0.01% | 2708 |
|
|
2020
Q3 | $195K | Buy |
8,541
+5,107
| +149% | +$126K | ﹤0.01% | 2768 |
|
|
2020
Q2 | $71.9K | Sell |
3,434
-8,951
| -72% | -$161K | ﹤0.01% | 2895 |
|
|
2020
Q1 | $173K | Buy |
12,385
+8,930
| +258% | +$177K | ﹤0.01% | 2936 |
|
|
2019
Q4 | $78.6K | Sell |
3,455
-640
| -16% | -$10.7K | ﹤0.01% | 3401 |
|
|
2019
Q3 | $47.7K | Buy |
4,095
+1,447
| +55% | +$18K | ﹤0.01% | 3501 |
|
|
2019
Q2 | $39.7K | Sell |
2,648
-2,292
| -46% | -$40K | ﹤0.01% | 3567 |
|
|
2019
Q1 | $86.6K | Buy |
+4,940
| New | +$78K | ﹤0.01% | 3211 |
|
|
2018
Q4 | – | Sell |
-682
| Closed | -$16.8K | – | 4400 |
|
|
2018
Q3 | $16.8K | Sell |
682
-86
| -11% | -$1.86K | ﹤0.01% | 3488 |
|
|
2018
Q2 | $15.1K | Buy |
768
+767
| +76,700% | +$14.5K | ﹤0.01% | 3610 |
|
|
2018
Q1 | $19 | Buy |
+1
| New | +$16 | ﹤0.01% | 4180 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$7 | – | 4286 |
|
|
2017
Q3 | $7 | Hold |
1
| – | – | ﹤0.01% | 4221 |
|
|
2017
Q2 | $8 | Sell |
1
-25
| -96% | -$186 | ﹤0.01% | 4235 |
|
|
2017
Q1 | $204 | Sell |
26
-220
| -89% | -$1.48K | ﹤0.01% | 3953 |
|
|
2016
Q4 | $6K | Sell |
246
-51
| -17% | -$1.46K | ﹤0.01% | 3640 |
|
|
2016
Q3 | $11.3K | Buy |
297
+124
| +72% | +$3.9K | ﹤0.01% | 3132 |
|
|
2016
Q2 | $5.13K | Buy |
+173
| New | +$6.08K | ﹤0.01% | 3258 |
|
Other funds holding RCKT
RI
NM
MC
BNP Paribas Financial Markets's RCKT Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Rocket Pharmaceuticals (RCKT) stake by 44% in Q2 2026, buying an estimated $392K and bringing the position to 387,065 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3119.
BNP Paribas Financial Markets first reported a position in RCKT in Q2 2016 and has held it in 39 quarters since. The position peaked at $5.36M in Q2 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.
- BNP Paribas Financial Markets held 387,065 shares of Rocket Pharmaceuticals worth $1.32M as of Q2 2026.
- BNP Paribas Financial Markets bought 117,859 Rocket Pharmaceuticals shares in Q2 2026, an estimated $392K.
- Rocket Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3119 holding.
- BNP Paribas Financial Markets first reported a position in Rocket Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
- BNP Paribas Financial Markets's Rocket Pharmaceuticals position peaked at $5.36M in Q2 2021.
- 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.